Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (1148)	2/11/1999 4:06:00 PM
From: Anthony Wong	Respond to of 2539

I'm trying to find out where that comes from (I mean the original source). Looks as if it was excerpted from a newspaper article.

To: Dan Spillane who wrote (1148)	2/11/1999 4:22:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

02/11 15:40 Justice reviewing Monsanto's Delta & Pine Land buy WASHINGTON, Feb 11 (Reuters) - The Justice Department's antitrust team is still reviewing life sciences firm Monsanto Co.'s <MTC.N> deal to acquire cotton seed maker Delta & Pine Land Co. <DLP.N>, a government spokeswoman said Thursday. "We are reviewing it," the spokeswoman said, adding she could not say anything more about the case because it's pending. When asked how much longer it will take for Justice to consider the case, the spokeswoman replied, "We don't give timelines." Monsanto, whose products include Roundup herbicides and Nutrasweet artificial sweeteners, agreed in May to acquire Delta and Pine Land in a stock swap. Analysts say the deal could raise red flags at Justice because Delta and Pine Land is the largest U.S. cotton seed maker, and Monsanto's Stoneville cotton unit is the second biggest. Monsanto said in January it planned to auction Stoneville in early 1999, a move analysts said would bring it closer to government approval of the acquisition. But company officials also said they had nothing new to report. "The conversations are ongoing with the Department of Justice," a spokeswoman for St. Louis-based Monsanto said.

To: Dan Spillane who wrote (1148)	2/11/1999 4:30:00 PM
From: Anthony Wong	Respond to of 2539

CELEBREX(TM) APPROVED IN MEXICO - NEW ARTHRITIS TREATMENT NOW CL PR Wire February 11, 1999, 2:37 p.m. ET ared for Market in Three Largest Countries in the Americas CHICAGO, Feb. 11 /PRNewswire/ -- G.D. Searle & Co., the pharmaceutical business unit of Monsanto Company (NYSE: MTC), and Pfizer Inc (NYSE: PFE) announced today that the Mexican Health Secretariat has approved Celebrex(TM) (celecoxib) for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and for the management of pain. The product has already been cleared by regulatory agencies in the United States and Brazil for the arthritis indications. "We are pleased that people with arthritis in Mexico will now have the benefit of this innovative and effective new product," said Al Heller, Searle's chief operating officer. "With approval in the U.S., Brazil, and now Mexico, Celebrex will now be available to arthritis patients in the three largest countries in the Americas." It is estimated that more than eight million of Mexico's 100 million people suffer from arthritis. Searle and Pfizer will promote Celebrex in all world markets except Japan. Additional Celebrex approvals are pending in more than 30 countries. Searle, a global leader in arthritis products and educational programs, is the pharmaceutical sector of Monsanto Company. Searle develops, produces and markets prescription pharmaceuticals, including major products to treat arthritis, cardiovascular disease, cancer and its complications and insomnia, and to promote women's health. For more information on Searle, access www.searlehealthnet.com. As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. In 1998, Monsanto reported sales of $8.6 billion and invested approximately $1 billion in research and development. Pfizer Inc is a research-based, global healthcare company. Pfizer discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier and more productive lives. The company has three business segments: health care, animal health and consumer health care, with products available in more than 150 countries. In 1998, the company reported revenues of over $13.5 billion and invested more than $2.2 billion in research and development. For more information on Pfizer, access www.pfizer.com. For complete prescribing information, please call 1-877-CELECOXIB or consult www.celebrex.com on the Internet. SOURCE Monsanto Company -0- 02/11/99 /CONTACT: Scarlett Foster of Monsanto, 314-694-2883; or Sharon Arnold of Chandler Chicco Agency, 212-229-8420, for Monsanto/ /Web site: pfizer.com /Web site: celebrex.com /Web site: searlehealthnet.com (MTC PFE) CO: Monsanto Company; G.D. Searle & Co.; Pfizer Inc ST: Illinois, Mexico IN: MTC HEA SU: PDT -0- Feb/11/1999 14:22 EOS (PRN) Feb/11/99 14:22 86

To: Dan Spillane who wrote (1148)	2/11/1999 4:51:00 PM
From: Anthony Wong	Respond to of 2539

Gruntal raised Pfizer's target based on Celebrex sales and momentum. When will it be MTC's turn? RESEARCH ALERT- Pfizer price target raised Thursday February 11, 3:52 pm Eastern Time CHICAGO, Feb 11 (Reuters) - Gruntal and Co. on Thursday reiterated pharmaceutical company Pfizer Inc. a strong buy and raised its one-year price target to $168 from $140, citing the success of Pfizer's launch of the arthritis drug Celebrex. --The launch of Celebrex had an extremely high 82,600 prescriptions recorded in its third week on the market, making it the second most successful new drug launch in history behind Pfizer's Viagra, Gruntal said in a research note. --Also, Pfizer's fourth quarter performance was outstanding from existing products without the benefit of the Celebrex launch in January, Gruntal said. --The Celebrex launch and these trends should provide Pfizer with the strongest momentum of any drug company into 1999, Gruntal said. --Shares of Pfizer were up 5-1/4 at 132 in afternoon trade. biz.yahoo.com